Oscotec Inc. (KOSDAQ: 039200)

Market Cap	1.36T
Revenue (ttm)	4.62B
Net Income (ttm)	-26.31B
Shares Out	38.19M
EPS (ttm)	-687.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	913,891
Open	34,400
Previous Close	34,350
Day's Range	34,350 - 38,200
52-Week Range	18,000 - 45,850
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Oscotec

Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1998
• Employees: 54
• Stock Exchange: KOSDAQ
• Ticker Symbol: 039200

Financial Performance

In 2023, Oscotec's revenue was 4.95 billion, a decrease of -2.20% compared to the previous year's 5.06 billion. Losses were -24.28 billion, -0.61% less than in 2022.